Compare MCR & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCR | AVXL |
|---|---|---|
| Founded | 1989 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.2M | 289.1M |
| IPO Year | N/A | 2013 |
| Metric | MCR | AVXL |
|---|---|---|
| Price | $6.00 | $3.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 95.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.84 | $2.61 |
| 52 Week High | $6.57 | $13.99 |
| Indicator | MCR | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 44.57 |
| Support Level | $5.84 | $2.93 |
| Resistance Level | $6.10 | $3.76 |
| Average True Range (ATR) | 0.05 | 0.20 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 25.00 | 44.71 |
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.